Turk Ilac ve Serum Sanayi AS
Turk Ilac Ve Serum Sanayi Anonim Sirketi produces and sells human tablets, parenteral solutions, nutritional solutions, amino acids, and other chemicals in Turkey. It also offers bulb, biological, and serum products, as well as medical devices. The company was founded in 2010 and is headquartered in Ankara, Turkey.
Turk Ilac ve Serum Sanayi AS (TRILC) - Total Liabilities
Latest total liabilities as of September 2025: TL4.21 Billion TRY
Based on the latest financial reports, Turk Ilac ve Serum Sanayi AS (TRILC) has total liabilities worth TL4.21 Billion TRY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Turk Ilac ve Serum Sanayi AS - Total Liabilities Trend (2018–2024)
This chart illustrates how Turk Ilac ve Serum Sanayi AS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Turk Ilac ve Serum Sanayi AS Competitors by Total Liabilities
The table below lists competitors of Turk Ilac ve Serum Sanayi AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Advice It Infinite Pcl
BK:ADVICE
|
Thailand | ฿2.21 Billion |
|
Gulshan Polyols Limited
NSE:GULPOLY
|
India | ₹6.50 Billion |
|
Mermaid Maritime Public Company Limited
PINK:MMMPF
|
USA | $221.69 Million |
|
Actinium Pharmaceuticals Inc
NYSE MKT:ATNM
|
USA | $42.37 Million |
|
Madison County Financial Inc
PINK:MCBK
|
USA | $-96.82 Million |
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
USA | $11.99 Million |
|
Harmony Electronics
TWO:8182
|
Taiwan | NT$2.25 Billion |
|
Tamul Multimedia Co. Ltd
KQ:093640
|
Korea | ₩36.88 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Turk Ilac ve Serum Sanayi AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Turk Ilac ve Serum Sanayi AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Turk Ilac ve Serum Sanayi AS (2018–2024)
The table below shows the annual total liabilities of Turk Ilac ve Serum Sanayi AS from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | TL2.07 Billion | +98.32% |
| 2023-12-31 | TL1.04 Billion | +117.69% |
| 2022-12-31 | TL479.65 Million | +62.34% |
| 2021-12-31 | TL295.46 Million | +17.71% |
| 2020-12-31 | TL250.99 Million | +24.35% |
| 2019-12-31 | TL201.84 Million | +58.46% |
| 2018-12-31 | TL127.38 Million | -- |